JP6466339B2 - 乳がんの処置におけるエリブリンの使用 - Google Patents
乳がんの処置におけるエリブリンの使用 Download PDFInfo
- Publication number
- JP6466339B2 JP6466339B2 JP2015544557A JP2015544557A JP6466339B2 JP 6466339 B2 JP6466339 B2 JP 6466339B2 JP 2015544557 A JP2015544557 A JP 2015544557A JP 2015544557 A JP2015544557 A JP 2015544557A JP 6466339 B2 JP6466339 B2 JP 6466339B2
- Authority
- JP
- Japan
- Prior art keywords
- negative
- breast cancer
- her2
- eribulin
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261733238P | 2012-12-04 | 2012-12-04 | |
| US61/733,238 | 2012-12-04 | ||
| US201361878204P | 2013-09-16 | 2013-09-16 | |
| US61/878,204 | 2013-09-16 | ||
| PCT/IB2013/002911 WO2014087230A1 (en) | 2012-12-04 | 2013-12-04 | Use of eribulin in the treatment of breast cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019002177A Division JP6678783B2 (ja) | 2012-12-04 | 2019-01-09 | 乳がんの処置におけるエリブリンの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016501213A JP2016501213A (ja) | 2016-01-18 |
| JP2016501213A5 JP2016501213A5 (cg-RX-API-DMAC7.html) | 2018-05-31 |
| JP6466339B2 true JP6466339B2 (ja) | 2019-02-06 |
Family
ID=50031376
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015544557A Active JP6466339B2 (ja) | 2012-12-04 | 2013-12-04 | 乳がんの処置におけるエリブリンの使用 |
| JP2019002177A Active JP6678783B2 (ja) | 2012-12-04 | 2019-01-09 | 乳がんの処置におけるエリブリンの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019002177A Active JP6678783B2 (ja) | 2012-12-04 | 2019-01-09 | 乳がんの処置におけるエリブリンの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20140163095A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2928464A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6466339B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20150090921A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2013353745A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112015012731A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2892780A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL239007B (cg-RX-API-DMAC7.html) |
| MX (1) | MX2015007185A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2689977C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014087230A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019089776A (ja) * | 2012-12-04 | 2019-06-13 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 乳がんの処置におけるエリブリンの使用 |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101434673B1 (ko) | 2004-06-03 | 2014-08-26 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 할리콘드린 b 유사체의 제조를 위한 중간체 |
| PE20120923A1 (es) | 2009-03-30 | 2012-08-27 | Eisai Randd Man Co Ltd | Composiciones farmaceuticas comprendiendo liposomas que contiene eribulina o una sal del mismo |
| CA2771403C (en) | 2009-08-19 | 2015-02-24 | Eisai R&D Management Co. Ltd. | Quinoline derivative-containing pharmaceutical composition |
| JP6038128B2 (ja) | 2011-06-03 | 2016-12-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー |
| JP6644479B2 (ja) * | 2014-06-24 | 2020-02-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | がん治療のための併用療法としてのエリブリンとs−1(もしくは5−fu)の使用 |
| EP3187491A4 (en) | 2014-08-28 | 2018-08-01 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
| US20180028662A1 (en) | 2015-02-25 | 2018-02-01 | Eisai R&D Management Co., Ltd. | Method for Suppressing Bitterness of Quinoline Derivative |
| MX386547B (es) * | 2015-03-04 | 2025-03-19 | Merck Sharp & Dohme | Combinación de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cáncer. |
| CA2988707C (en) | 2015-06-16 | 2023-10-10 | Eisai R&D Management Co., Ltd. | Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer |
| CN108135894B (zh) | 2015-08-20 | 2021-02-19 | 卫材R&D管理有限公司 | 肿瘤治疗剂 |
| WO2017188350A1 (ja) | 2016-04-28 | 2017-11-02 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍の成長を抑制する方法 |
| CN110072528B (zh) | 2017-02-08 | 2022-04-26 | 卫材R&D管理有限公司 | 治疗肿瘤的药物组合物 |
| UA126029C2 (uk) * | 2017-02-20 | 2022-08-03 | Поліфор Аґ | Фармацевтичні комбінації для лікування раку |
| WO2018212202A1 (en) | 2017-05-16 | 2018-11-22 | Eisai R&D Management Co., Ltd. | Treatment of hepatocellular carcinoma |
| EP3654967A4 (en) * | 2017-07-21 | 2021-04-21 | Eisai R&D Management Co., Ltd. | USE OF EIBULIN AND CYCLINE-DEPENDENT KINASE INHIBITORS IN THE TREATMENT OF CANCER |
| EP3713565A1 (en) * | 2017-11-20 | 2020-09-30 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| BR112020015909A2 (pt) * | 2018-02-05 | 2020-12-15 | Tesaro, Inc. | Formulações pediátricas de niraparib e métodos de tratamento pediátrico |
| CN112262157A (zh) * | 2018-03-09 | 2021-01-22 | 加利福尼亚大学董事会 | 化药抗性癌症的组合治疗 |
| CN113271977A (zh) * | 2018-11-09 | 2021-08-17 | G1治疗公司 | 使用艾日布林和选择性cdk4/6抑制剂组合治疗癌症的治疗方案 |
| ES3075649T3 (en) | 2019-07-26 | 2026-08-06 | Eisai R&D Man Co Ltd | Pharmaceutical composition for treating tumor |
| US11083705B2 (en) | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| WO2025106586A1 (en) * | 2023-11-13 | 2025-05-22 | Luxvitae Therapeutics Inc. | Macrocyclic ketone compounds and applications thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2632433C (en) | 1998-06-17 | 2012-02-07 | Eisai R & D Management Co., Ltd. | Methods for preparing macrocyclic analogs and intermediates for preparing same |
| US6653341B1 (en) | 1998-06-17 | 2003-11-25 | Eisai Co., Ltd. | Methods and compositions for use in treating cancer |
| KR101434673B1 (ko) | 2004-06-03 | 2014-08-26 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 할리콘드린 b 유사체의 제조를 위한 중간체 |
| CN103169729A (zh) * | 2005-02-18 | 2013-06-26 | 阿布拉科斯生物科学有限公司 | 治疗剂的组合和给予方式以及联合治疗 |
| CA2646156C (en) * | 2006-03-22 | 2016-05-24 | Medigene Ag | Treatment of triple receptor negative breast cancer |
| EP2578576B9 (en) | 2007-10-03 | 2016-09-14 | Eisai R&D Management Co., Ltd. | Intermediates for the synthesis of halichondrin B analogs |
| RU2517167C2 (ru) | 2008-04-04 | 2014-05-27 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Аналоги галихондрина в |
| US8203010B2 (en) | 2010-01-26 | 2012-06-19 | Eisai R&D Management Co., Ltd. | Compounds useful in the synthesis of halichondrin B analogs |
| EP2686441B1 (en) * | 2011-03-18 | 2019-05-08 | Eisai R&D Management Co., Ltd. | Methods and uses for predicting response to eribulin |
| AU2013353745A1 (en) * | 2012-12-04 | 2015-06-11 | Eisai R&D Management Co., Ltd. | Use of eribulin in the treatment of breast cancer |
-
2013
- 2013-12-04 AU AU2013353745A patent/AU2013353745A1/en not_active Abandoned
- 2013-12-04 US US14/096,827 patent/US20140163095A1/en not_active Abandoned
- 2013-12-04 JP JP2015544557A patent/JP6466339B2/ja active Active
- 2013-12-04 CA CA2892780A patent/CA2892780A1/en not_active Abandoned
- 2013-12-04 EP EP13826752.1A patent/EP2928464A1/en not_active Withdrawn
- 2013-12-04 RU RU2015126539A patent/RU2689977C2/ru active
- 2013-12-04 KR KR1020157017971A patent/KR20150090921A/ko not_active Ceased
- 2013-12-04 MX MX2015007185A patent/MX2015007185A/es unknown
- 2013-12-04 WO PCT/IB2013/002911 patent/WO2014087230A1/en not_active Ceased
- 2013-12-04 BR BR112015012731A patent/BR112015012731A2/pt not_active Application Discontinuation
-
2015
- 2015-05-25 IL IL239007A patent/IL239007B/en active IP Right Grant
-
2018
- 2018-08-09 AU AU2018214086A patent/AU2018214086B2/en not_active Withdrawn - After Issue
-
2019
- 2019-01-09 JP JP2019002177A patent/JP6678783B2/ja active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019089776A (ja) * | 2012-12-04 | 2019-06-13 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 乳がんの処置におけるエリブリンの使用 |
Also Published As
| Publication number | Publication date |
|---|---|
| IL239007A0 (en) | 2015-07-30 |
| KR20150090921A (ko) | 2015-08-06 |
| MX2015007185A (es) | 2017-09-05 |
| EP2928464A1 (en) | 2015-10-14 |
| RU2015126539A (ru) | 2017-01-13 |
| JP2016501213A (ja) | 2016-01-18 |
| RU2689977C2 (ru) | 2019-05-30 |
| IL239007B (en) | 2018-04-30 |
| US20140163095A1 (en) | 2014-06-12 |
| BR112015012731A2 (pt) | 2017-07-11 |
| AU2018214086A1 (en) | 2018-08-23 |
| CA2892780A1 (en) | 2014-06-12 |
| AU2018214086B2 (en) | 2020-07-09 |
| AU2013353745A1 (en) | 2015-06-11 |
| JP2019089776A (ja) | 2019-06-13 |
| WO2014087230A1 (en) | 2014-06-12 |
| JP6678783B2 (ja) | 2020-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6678783B2 (ja) | 乳がんの処置におけるエリブリンの使用 | |
| Wang et al. | Targeted therapeutic options and future perspectives for HER2-positive breast cancer | |
| Saxena et al. | ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective | |
| Rastelli et al. | Triple-negative breast cancer: current state of the art | |
| Armstrong et al. | Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer | |
| Nahta et al. | Growth factor receptors in breast cancer: potential for therapeutic intervention | |
| Colozza et al. | Achievements in systemic therapies in the pregenomic era in metastatic breast cancer | |
| Al Nakouzi et al. | Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies | |
| Johnston | Enhancing the efficacy of hormonal agents with selected targeted agents | |
| JP2018514549A (ja) | 癌を治療するための方法 | |
| JP2014508782A (ja) | ホルモン不応性乳癌の治療におけるegfrファミリー受容体の阻害剤の使用 | |
| Rimawi et al. | A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer | |
| Miller et al. | The role of chemotherapy for metastatic breast cancer | |
| US20240139196A1 (en) | Combination treatments in difficult to treat patients with advanced and/or metastatic trop-2 overexpressing cancers | |
| JP2021502982A (ja) | 癌治療 | |
| KR20170137886A (ko) | 세리반투맙에 의한 병용 치료 | |
| Kheraldine et al. | Targeting HER2-positive breast cancer cells by a combination of dasatinib and BMS-202: Insight into the molecular pathways | |
| JP2016519157A (ja) | ガネテスピブを用いる特定癌の治療レジメン | |
| Brufsky et al. | A randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer | |
| TW201722423A (zh) | 乳癌治療 | |
| Semiglazov et al. | Neoadjuvant systemic therapy in breast cancer | |
| Oosting et al. | 221 DISCUSSION 89Zr-bevacizumab PET imaging in renal cell carcinoma patients: feasibility of tumor VEGF quantification | |
| Roisin Connolly MB et al. | A multidisciplinary approach to neoadjuvant therapy for primary operable breast cancer: Challenges and opportunities | |
| Arnedos et al. | Emerging targeted therapies for breast cancer | |
| WO2025029980A1 (en) | Inhibition of hypoxia signaling pathway by plk1 inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161201 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161201 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170808 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20171010 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171212 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180209 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20180410 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180918 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181116 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181211 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190109 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6466339 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R157 | Certificate of patent or utility model (correction) |
Free format text: JAPANESE INTERMEDIATE CODE: R157 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |